BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 36642627)

  • 1. AGA Clinical Practice Update on Diagnosis and Management of Acute Hepatic Porphyrias: Expert Review.
    Wang B; Bonkovsky HL; Lim JK; Balwani M
    Gastroenterology; 2023 Mar; 164(3):484-491. PubMed ID: 36642627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AGA Clinical Practice Update on the Evaluation and Management of Acute Kidney Injury in Patients With Cirrhosis: Expert Review.
    Flamm SL; Wong F; Ahn J; Kamath PS
    Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2707-2716. PubMed ID: 36075500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Challenges in diagnosis and management of acute hepatic porphyrias: from an uncommon pediatric onset to innovative treatments and perspectives.
    Marcacci M; Ricci A; Cuoghi C; Marchini S; Pietrangelo A; Ventura P
    Orphanet J Rare Dis; 2022 Apr; 17(1):160. PubMed ID: 35392955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical features of acute attacks, chronic symptoms, and long-term complications among patients with acute hepatic porphyria in Japan: a real-world claims database study.
    Horie Y; Yasuoka Y; Adachi T
    Orphanet J Rare Dis; 2023 Dec; 18(1):384. PubMed ID: 38066651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Aminolevulinate dehydratase porphyria: Update on hepatic 5-aminolevulinic acid synthase induction and long-term response to hemin.
    Lahiji AP; Anderson KE; Chan A; Simon A; Desnick RJ; Ramanujam VMS
    Mol Genet Metab; 2020 Dec; 131(4):418-423. PubMed ID: 33199206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.
    Balwani M; Sardh E; Ventura P; Peiró PA; Rees DC; Stölzel U; Bissell DM; Bonkovsky HL; Windyga J; Anderson KE; Parker C; Silver SM; Keel SB; Wang JD; Stein PE; Harper P; Vassiliou D; Wang B; Phillips J; Ivanova A; Langendonk JG; Kauppinen R; Minder E; Horie Y; Penz C; Chen J; Liu S; Ko JJ; Sweetser MT; Garg P; Vaishnaw A; Kim JB; Simon AR; Gouya L;
    N Engl J Med; 2020 Jun; 382(24):2289-2301. PubMed ID: 32521132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AGA Clinical Practice Update on Management of Refractory Celiac Disease: Expert Review.
    Green PHR; Paski S; Ko CW; Rubio-Tapia A
    Gastroenterology; 2022 Nov; 163(5):1461-1469. PubMed ID: 36137844
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disease burden in patients with acute hepatic porphyria: experience from the phase 3 ENVISION study.
    Wang B; Ventura P; Takase KI; Thapar M; Cassiman D; Kubisch I; Liu S; Sweetser MT; Balwani M
    Orphanet J Rare Dis; 2022 Aug; 17(1):327. PubMed ID: 36028858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AGA Clinical Practice Update on the Diagnosis and Management of Extraesophageal Gastroesophageal Reflux Disease: Expert Review.
    Chen JW; Vela MF; Peterson KA; Carlson DA
    Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1414-1421.e3. PubMed ID: 37061897
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case-based discussion of the acute hepatic porphyrias: Updates on pathogenesis, diagnosis and management.
    Balwani M; Keel S; Meissner P; Sonderup M; Stein P; Yasuda M
    Liver Int; 2024 Apr; ():. PubMed ID: 38618923
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AGA Clinical Practice Update on Evaluation and Management of Belching, Abdominal Bloating, and Distention: Expert Review.
    Moshiree B; Drossman D; Shaukat A
    Gastroenterology; 2023 Sep; 165(3):791-800.e3. PubMed ID: 37452811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria.
    Sardh E; Harper P
    J Intern Med; 2022 May; 291(5):593-610. PubMed ID: 35067977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AGA Clinical Practice Update on the Use of Vasoactive Drugs and Intravenous Albumin in Cirrhosis: Expert Review.
    Garcia-Tsao G; Abraldes JG; Rich NE; Wong VW
    Gastroenterology; 2024 Jan; 166(1):202-210. PubMed ID: 37978969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AGA Clinical Practice Update on the Epidemiology, Evaluation, and Management of Exocrine Pancreatic Insufficiency: Expert Review.
    Whitcomb DC; Buchner AM; Forsmark CE
    Gastroenterology; 2023 Nov; 165(5):1292-1301. PubMed ID: 37737818
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AGA Clinical Practice Update on the Role of Noninvasive Biomarkers in the Evaluation and Management of Nonalcoholic Fatty Liver Disease: Expert Review.
    Wattacheril JJ; Abdelmalek MF; Lim JK; Sanyal AJ
    Gastroenterology; 2023 Oct; 165(4):1080-1088. PubMed ID: 37542503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AGA Clinical Practice Update: Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Lean Individuals: Expert Review.
    Long MT; Noureddin M; Lim JK
    Gastroenterology; 2022 Sep; 163(3):764-774.e1. PubMed ID: 35842345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Guide and Update on Porphyrias.
    Stölzel U; Doss MO; Schuppan D
    Gastroenterology; 2019 Aug; 157(2):365-381.e4. PubMed ID: 31085196
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute porphyrias in the USA: features of 108 subjects from porphyrias consortium.
    Bonkovsky HL; Maddukuri VC; Yazici C; Anderson KE; Bissell DM; Bloomer JR; Phillips JD; Naik H; Peter I; Baillargeon G; Bossi K; Gandolfo L; Light C; Bishop D; Desnick RJ
    Am J Med; 2014 Dec; 127(12):1233-41. PubMed ID: 25016127
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 20.